COVID-19 Impact Assessment: Health and Life Sciences Industry Report

The COVID-19 pandemic has triggered a rapid increase in diagnostic and treatment needs, with the high transmission rate of the virus leading to a surge in cases and deaths worldwide. Despite the challenges, researchers and scientists are working tirelessly to develop safe and effective treatment options, with vaccines and anti-virals being the most explored treatment options currently being investigated. The report analyzes the diagnosis and treatment areas, with the diagnosis segment divided into PCR-based testing and antibody testing, and the treatment area segmented into vaccines, immunotherapies, anti-virals, cell-based therapies, and other therapies.

Key Takeaways:

• The antibodies, protein-based vaccines, anti-viral, cell-based therapies are expected to lead the COVID-19 treatment pipeline.
• The high transmission rate of coronavirus has led to a rapid increase in COVID-19 cases and deaths worldwide, triggering the rapid growth in diagnostic and treatment needs.
• The lack of information on the novel virus, such as biological, genetic information, duration of immunity granted in recovered patients, has been a key challenge in achieving a successful solution.
• The diagnosis segment is further divided into PCR-based testing and antibody testing, while the treatment area is segmented into vaccines, immunotherapies, anti-virals, cell-based therapies, and other therapies.
• Vaccines and anti-virals are the most explored treatment options currently being investigated by researchers worldwide.
• The study evaluates product pipeline based on development stage, with COVID-19 crisis affecting various countries differently based on traveller volumes, responsiveness of government to the infections, and capabilities of healthcare systems.
• Geographically, North America has been the most affected region, primarily attributed to the U.S. being the most affected country having most number of confirmed cases as well as deaths, globally.
• The governments across the globe are implementing actions to overcome the situation, with primary focus on restriction on people movement, setting up emergency screens and treatment centres, creating mass awareness, and accelerating research and development for COVID-19.
• Some of the key players engaged in the COVID-19 diagnosis and treatment development include Roche Holding AG, Thermo Fisher Scientific, Inc., Abbott Laboratories, Becton, Dickinson and Company, AbbVie Corporation, Gilead Sciences, Inc., Eli Lilly and Company, Moderna, Inc., Novavax, Inc., Medicago, Inc., Inovio Pharmaceuticals, Inc., GlaxoSmithKline, Sanofi S.A., Johnson & Johnson, Sorrento Therapeutics, Inc., AstraZeneca Plc, Pfizer, Inc., CTI Biopharma Corporation, OncoImmune, Inc., Athersys, Inc., Celularity, Inc., Pluristem Therapeutics, and Takeda Pharmaceuticals Company Ltd.

Statistics:

• The COVID-19 pandemic has affected over 100 countries worldwide, with over 5 million confirmed cases and over 300,000 deaths.
• The U.S. has been the most affected country, with over 1.5 million confirmed cases and over 90,000 deaths.
• The global economic impact of the pandemic is estimated to be over $3 trillion, with GDP decline, increase in unemployment rates, and increase in inflation rates.
• The U.S. government has invested nearly $1 billion to support coronavirus vaccine development, while the U.K. government has announced GBP 24.6 million funding for rapid research responses.
• The North America region has been the most affected, with over 80% of the global cases and deaths.

Sources:

• Meticulous Research's COVID-19 (Coronavirus) Impact Assessment: Health and Life Sciences (Coronavirus, Epidemiology, Economic Impact), Product Pipeline (Diagnosis (PCR Testing, Antibody testing), Treatment (Immunotherapy, Vaccines, Antiviral, Cell-based, Plasma therapy), and Geography
• Meticulous Research's COVID-19 Impact Assessment, by Geography: North America, Europe, Asia-Pacific (APAC), Rest of the World (RoW)